CTI BioPharma (CTIC) Announces Withdrawal of EMA Application for Pacritinib for Treatment of Myelofibrosis Following Results of CHMP Oral Explanation

February 1, 2019 7:09 AM
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles